Search This Blog

Tuesday, July 14, 2020

FDA Ad Com thumbs up on Glaxo’s belantamab mafodotin

The FDA’s Oncologic Drugs Advisory Committee voted 12-0 that the benefits outweigh the risks of GlaxoSmithKline’s (GSK +1.6%) antibody-drug conjugate belantamab mafodotin for the last-line line treatment of multiple myeloma.
Related ticker: Karyopharm Therapeutics (KPTI +8.4%)

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)